2-Butyl-4-Chloro-5-Formylimidazole (BCFI) CAS 83857-96-9 Losartan Potassium intermedia Factory
Supple Losartan Potassium et intermedias Related
Losartan Potassium CAS 124750-99-8
2-Butyl-4-Chloro-5-Formylimidazole (BCFI) CAS 83857-96-9
High Quality, Commercial Production
| Nomen chemicum | 2-Butyl-4-chloro-5-formylimidazole |
| Synonyma | BCFI;2-Butyl-5-chloro-1H-imidazole-4-carboxaldehyde |
| CAS Number | 83857-96-9 |
| CATTUS Number | RF-PI319 |
| Stock Status | In Stock, Productio Ascendite ad Tons |
| Formulae hypotheticae | C8H11ClN2O |
| M. Pondus | 186.64 |
| Density | 1.240 |
| Solubilitas | Solutum in Methanol et Chloroforme;Leviter solutum in aqua |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Aspectus | Lux Yellow ad Yellow Crystallina pulveris |
| Lepidium sativum | Oportet quod ad Reference Standard |
| Liquescens punctum | 96.0~99.0℃(lit.) |
| Humor Content (KF) | ≤0.50% |
| Imidazolol | Non Results |
| Valerianitile | ≤0.15% |
| una immunditia | ≤0.15% |
| Totalis immunditiae | ≤1.0% |
| Puritas / Analysis Methodus | ≥99.0% (per HPLC) |
| Test Standard | Enterprise Standard |
| Consuetudinem | Intermedium Losartan Potassium (CAS 124750-99-8) Antihypertensive |
sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Lucem protege, humorem.
2-Butyl-4-chloro-5-formylimidazole (BCFI) (CAS 83857-96-9) est medium Losartan Potassii (CAS 124750-99-8), receptor angiotensin II contrarius.Losartan potassium sal potassium losartanae cum actione antihypertensiva, quae maxime adhibetur in therapia sanguinis pressionis altae (hypertensionis) et nephropathiae diabeticae.Remittit venas laxando ut sanguis facilius fluat.Valet etiam ad auxilium renum ab detrimento diabete tuendos et pericula plagae in aegros hypertensione et dilatatione myocardiaca laborantibus.Praeter recentem studium losartan utilem esse suggessit aetati adversae dysfunctioni repraesento in conservando pressione sanguinis normali et energiae cellularum usu in mitochondriaco et probabiliter adhiberi potest ut hypertrophia ventricularis sinistri tractare possit.
